Sareum Holdings plc
("Sareum" or the "Company")
Appointment of Joint Broker
Cambridge, UK, 18 December 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce the appointment of Oberon Capital as a Joint Corporate Broker with immediate effect. Oberon Capital is a trading name of Oberon Investments Limited.
Strand Hanson Limited and Hybridan LLP will continue to act as the Company's Nominated Adviser and Joint Corporate Broker, respectively.
- Ends -
For further information, please contact:
| Sareum Holdings plc Stephen Parker, Executive Chairman |
01223 497700 ir@sareum.co.uk |
| Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman |
020 7409 3494 |
| Oberon Capital (J oint Broker) Mike Seabrook / Nick Lovering Hybridan LLP (J oint Broker) Claire Noyce |
020 3179 5300 020 3764 2341 |
| ICR Healthcare (Financial PR) Jessica Hodgson / Davide Salvi / K umail Waljee |
0203 709 5700 |
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has completed Phase 1 clinical development and is readying for phase 2 trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com